ROIV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'25 | $-0.45 | - | - |
| Q1'25 | $-0.16 | $-0.22 | -33.6% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'25 | $4M | - | - |
| Q1'25 | - | $8M | - |
ROIV|Monthly Returns
Market Data
ROIV Stock Snapshot
- Market cap
- 28.73B
- Day range
- $38.72 – $39.92
- News sentiment
- 82/100 · Bullish
- Analyst target
- $47.79 (+22.4%)
- Consensus
- Buy · 21 analysts
Roivant Sciences Ltd. screens well technically, with price sitting in the upper part of its 52-week range. Earnings and guidance carry more weight than macro data at this capitalisation.
Behaviour On Record
What ROIV's own history says about today's numbers
- Realized volatility (21d)
- 63.5% 69th pct
- Below its peak
- -6.5%
- vs 200-day average
- +32.5%
- Up days (1y)
- 53%
Roivant Sciences Ltd. is currently running 63.5% annualised volatility over the last 21 sessions. Measured against ROIV's own 6 years of daily returns rather than a market-wide average, that is the 69th percentile — a little above its own norm, against a typical reading of 45.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ROIV is trading -6.5% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -35.6%, and the deepest was -71.6% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +32.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 69th percentile — a somewhat wider gap than its own norm. Over the past year ROIV closed higher on 53% of sessions, and it is currently 2 sessions into a falling streak.
On September specifically: over 6 years of records, ROIV finished the month higher 3 of 6 times, with a median return of +0.1% and an average of +3.6%. Its strongest month historically has been December at +10.0% on average, its weakest March at -8.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ROIV has opened more than 2% away from the prior close in 290 of 1,451 sessions (20.0% of the time), with the largest gaps running +14.9% and -10.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 1,452 daily closes between 2020-12-08 and 2026-09-21, split-adjusted, recomputed daily. Percentiles are against ROIV's own 6-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ROIV's sector?
Roivant Sciences Ltd. sits in the Health Care sector, currently ranked 5th of 11 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #5 of 11
- Sector state
- Improving
- Sector rotation score
- 80
Analyst Rating Changes
Are analysts turning bullish or bearish on ROIV?
Stifel most recently initiated coverage on Roivant Sciences Ltd. to Buy on Sep 17, 2026 with a price target of $51. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Stifel — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
ROIV Competitive Positioning
- ROIVyou're hereRoivant Sciences Ltd.$28.7B-1.86%
- MRNAModerna, Inc.$61.5B+12.60%
- INCYIncyte Corporation$25.4B-0.36%
- BNTXBioNTech SE$24.8B+2.61%
- ABCLAbCellera Biologics Inc.$4.1B-0.40%
- RXRXRecursion Pharmaceuticals Inc.$2.1B+3.13%
